Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Previous studies based on a single measure of fasting plasma glucose (FPG) showed an inconsistent conclusion about the association between FPG and osteoporosis risk. Not accounting for time-varying and cumulative average of FPG over time could bias the true relation between FPG and osteoporosis. Our study aims to investigate the association between the trajectories of FPG and osteoporosis risk for non-diabetic and diabetic populations.

Methods: A total of 18,313 participants who attended physical examinations during 2008-2018 were included. They were free of osteoporosis at their first physical examination and followed until their last physical examination before December 31, 2018. We recorded their incidence of osteoporosis and at least three FPG values during follow-up. Their longitudinal FPG trajectories were identified by the latent class growth analysis model based on the changes in FPG. Multivariable logistic regression models were used to analyze the association between the trajectories of FPG and osteoporosis diagnosed in the follow-up physical examination in both non-diabetics and diabetics.

Results: There were 752 incident osteoporosis among 16,966 non-diabetic participants, and 57 incident osteoporosis among 1,347 diabetic participants. Among non-diabetics, the elevated-increasing FPG trajectory was negatively associated with osteoporosis risk in women (odds ratio (OR), 0.62; 95% confidence interval (CI), 0.43-0.88). Premenopausal women with elevated-increasing FPG trajectory had lower osteoporosis risk than those women with normal-stable FPG trajectory (OR, 0.41; 95% CI, 0.20-0.88), while this association was insignificant in postmenopausal women. Among diabetics, those whose longitudinal FPG is kept at a very high level had the highest risk of osteoporosis (OR, 3.09; 95% CI, 1.16-8.22), whereas those whose FPG starts with the high level and keeps on increasing did not exhibit a significantly increased risk (OR, 1.75; 95% CI, 0.81-3.76) compared with those who keep stable moderate-high level of FPG, except in men (OR, 2.49; 95% CI, 1.02-6.12).

Conclusion: Distinct trajectories of FPG are associated with differential risk of osteoporosis in non-diabetic and diabetic populations. Controlling a proper FPG level in different populations is necessary for osteoporosis prevention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679646PMC
http://dx.doi.org/10.3389/fpubh.2022.960928DOI Listing

Publication Analysis

Top Keywords

fpg
17
fpg osteoporosis
16
osteoporosis risk
16
osteoporosis
14
association trajectories
12
risk osteoporosis
12
non-diabetic diabetic
12
trajectories fpg
12
physical examination
12
fpg trajectory
12

Similar Publications

Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).

Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group ( View Article and Find Full Text PDF

Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.

Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.

View Article and Find Full Text PDF

Purpose: While SGLT-2i and GLP-1RA show cardiorenal benefits, their comparative efficacy in elderly type 2 diabetes mellitus (T2DM) patients remains uncertain. This study aimed to compare SGLT-2i and GLP-1RA on cardiovascular and renal outcomes in elderly T2DM patients.

Methods: This retrospective study analyzed 1,015 propensity score-matched elderly T2DM patients (SGLT-2i group: n = 583; GLP-1RA group: n = 432).

View Article and Find Full Text PDF

[Clinical efficacy analysis of Shibao Decoction in the treatment of late-onset hypogonadism with kidney essence deficiency].

Zhonghua Nan Ke Xue

July 2025

Department of Surgery, Yinchuan Hospital of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia 750001, China.

Objective: To evaluate the clinical efficacy of "Shibao Decoction" in the management of late-onset hypogonadism (LOH) caused by deficiency of kidney essence.

Methods: Sixty male patients with late-onset hypogonadism of kidney essence deficiency type were randomly assigned to the treatment group and the control group, each with 30 cases. The patients in treatment group were treated with oral Shibao Decoction, while the control group was treated with oral Testosterone Undecanoate Capsules.

View Article and Find Full Text PDF

Correlation between thyroid sensitivity indices and bone metabolism in newly diagnosed middle aged and elderly patients with type 2 diabetes mellitus with normal thyroid function.

BMC Endocr Disord

September 2025

Department of Endocrinology and Metabolism, Jiangxi Medical College, The Second Affiliated Hospital, Nanchang University, Nanchang City, 330006, Jiangxi Province, China.

Objective: To investigate the association between thyroid hormone sensitivity indices and bone metabolism markers in newly diagnosed middle-aged and elderly type 2 diabetes mellitus (T2DM) patients with normal thyroid function.

Method: We retrospectively analyzed 350 newly diagnosed T2DM patients (≥ 45 years), stratified by bone mineral density into Group A (normal bone density group) and Group B (low bone mass and osteoporosis group). General data and clinical biochemical parameters were collected: free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), osteocalcin (OC), bone-specific alkaline phosphatase (BALP), serum calcium (Ca), serum phosphorus (P), fasting plasma glucose (FPG), glycosylated hemoglobinA1c (HbA1c), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum creatinine (SCr), serum uric acid (SUA), and estimated Glomerular Filtration Rate (eGFR).

View Article and Find Full Text PDF